The effects of pramipexole on prepulse inhibition and locomotor activity in C57BL/6J mice

Behavioural Pharmacology

Volumn 21, Issue 2, 2010, Pages 135-143

  Chang, Wei Li ^a   Geyer, Mark A ^a   Buell, Mahalah R ^a   Weber, Martin ^a   Swerdlow, Neal R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

C57BL 6 mouse; D3 receptor; Dopamine; Exploratory behavior; Locomotor behavior; Pramipexole; Prepulse inhibition

Indexed keywords

APOMORPHINE; DOPAMINE 3 RECEPTOR; PRAMIPEXOLE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; LOCOMOTION; MALE; MOUSE; NONHUMAN; PREPULSE INHIBITION; STARTLE REFLEX;

ANIMALS; APOMORPHINE; BENZOTHIAZOLES; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; INHIBITION (PSYCHOLOGY); MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; SENSORY GATING; STARTLE REACTION;

EID: 77949850461     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e328337be7e     Document Type: Article

References (52)

1. Bitsios P, Giakoumaki SG, Frangou S (2005). The effects of dopamine agonists on prepulse inhibition in healthy men depend on baseline PPI values. Psychopharmacology (Berl) 182:144-152.
2. Brea J, Castro M, Loza MI, Masaguer CF, Ravina E, Dezi C, et al. (2006). QF2004B, a potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine. Neuropharmacology 51:251-262.
3. Caldwell HK, Stephens SL, Young WS 3rd (2009). Oxytocin as a natural antipsychotic: a study using oxytocin knockout mice. Mol Psychiatry 14:190-196.
4. Carta AR, Gerfen CR, Steiner H (2000). Cocaine effects on gene regulation in the striatum and behavior: increased sensitivity in D3 dopamine receptor-deficient mice. Neuroreport 11:2395-2399.
5. Chang WL, Swerdlow NR, Breier MR, Thangaraj N, Weber M (2009). Parametric approaches towards understanding the effects of the preferential D3 receptor agonist pramipexole on prepulse inhibition in rats. Abstr Soc Neurosci 843:9.
6. Corbin AE, Pugsley TA, Akunne HC, Whetzel SZ, Zoski KT, Georgic LM, et al. (1998). Pharmacological characterization of PD 152255, a novel dimeric benzimidazole dopamine D3 antagonist. Pharmacol Biochem Behav 59:487-493.
7. Culm KE, Lugo-Escobar N, Hope BT, Hammer RP Jr (2004). Repeated quinpirole treatment increases cAMP-dependent protein kinase activity and CREB phosphorylation in nucleus accumbens and reverses quinpirole-induced sensorimotor gating deficits in rats. Neuropsychopharmacology 29:1823-1830.
8. Curzon P, Decker MW (1998). Effects of phencyclidine (PCP) and (+)MK-801 on sensorimotor gating in CD-1 mice. Prog Neuropsychopharmacol Biol Psychiatry 22:129-146.
9. Depoortere R, Bardin L, Auclair AL, Kleven MS, Prinssen E, Colpaert F, et al. (2007). F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia. Br J Pharmacol 151:253-265.
10. Doherty JM, Masten VL, Powell SB, Ralph RJ, Klamer D, Low MJ, Geyer MA (2008). Contributions of dopamine D1, D2, and D3 receptor subtypes to the disruptive effects of cocaine on prepulse inhibition in mice. Neuropsycho-pharmacology 33:2648-2656.
11. Geyer MA, Dulawa SC (2003). Assessment of murine startle reactivity, prepulse inhibition, and habituation. Curr Protoc Neurosci 8:17.
12. Geyer MA, Russo PV, Masten VL (1986). Multivariate assessment of locomotor behavior: pharmacological and behavioral analyses. Pharmacol Biochem Behav 25:277-288.
13. Glickstein SB, Schmauss C (2004). Effect of methamphetamine on cognition and repetitive motor behavior of mice deficient for dopamine D2 and D3 receptors. Ann N Y Acad Sci 1025:110-118.
14. Harrison SJ, Nobrega JN (2009). Differential susceptibility to ethanol and amphetamine sensitization in dopamine D3 receptor-deficient mice. Psycho-pharmacology (Berl) 204:49-59.
15. Karasinska JM, George SR, Cheng M, O'Dowd BF (2005). Deletion of dopamine D1 and D3 receptors differentially affects spontaneous behaviour and cocaine-induced locomotor activity, reward and CREB phosphorylation. Eur J Neurosci 22:1741-1750.
16. Kitagawa K, Kitamura Y, Miyazaki T, Miyaoka J, Kawasaki H, Asanuma M, et al. (2009). Effects of pramipexole on the duration of immobility during the forced swim test in normal and ACTH-treated rats. Naunyn Schmiedebergs Arch Pharmacol 380:59-66.
17. Le Foll B, Frances H, Diaz J, Schwartz JC, Sokoloff P (2002). Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. Eur J Neurosci 15:2016-2026.
18. Leggio GM, Micale V, Drago F (2008). Increased sensitivity to antidepressants of D3 dopamine receptor-deficient mice in the forced swim test (FST). Eur Neuropsychopharmacol 18:271-277.
19. Lehr E (2002). Potential antidepressant properties of pramipexole detected in locomotor and operant behavioral investigations in mice. Psychopharmaco-logy (Berl) 163:495-500.
20. Maj J, Rogoz Z, Skuza G, Kolodziejczyk K (1997). The behavioural effects of pramipexole, a novel dopamine receptor agonist. Eur J Pharmacol 324:31-37.
21. Malone DT, Long LE, Taylor DA (2004). The effect of SR 141716 and apomorphine on sensorimotor gating in Swiss mice. Pharmacol Biochem Behav 77:839-845.
22. Martin S, Markus MA, Morris BJ, Davisson RL, Lawrence AJ, Van den Buuse M (2008). Does angiotensin interact with dopaminergic mechanisms in the brain to modulate prepulse inhibition in mice? Neuropharmacology 54:399-404.
23. McNamara RK, Levant B, Taylor B, Ahlbrand R, Liu Y, Sullivan JR, et al. (2006). C57BL/6J mice exhibit reduced dopamine D3 receptor-mediated locomotor-inhibitory function relative to DBA/2J mice. Neuroscience 143:141-153.
24. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (2002). Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303:791-804.
25. Park WK, Jeong D, Cho H, Lee SJ, Cha MY, Pae AN, et al. (2005). KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia. Pharmacol Biochem Behav 82:361-372.
26. Piercey MF, Lum JT, Hoffmann WE, Carlsson A, Ljung E, Svensson K (1992). Antagonism of cocaine's pharmacological effects by the stimulant dopaminergic antagonists, (+)-AJ76 and (+)-UH232. Brain Res 588:217-222.
27. Piercey MF, Hoffmann WE, Smith MW, Hyslop DK (1996). Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol 312:35-44.
28. Pritchard LM, Logue AD, Hayes S, Welge JA, Xu M, Zhang J, et al. (2003). 7-OH-DPAT and PD 128907 selectively activate the D3 dopamine receptor in a novel environment. Neuropsychopharmacology 28:100-107.
29. Pritchard LM, Newman AH, McNamara RK, Logue AD, Taylor B, Welge JA, et al. (2007). The dopamine D3 receptor antagonist NGB 2904 increases spontaneous and amphetamine-stimulated locomotion. Pharmacol Biochem Behav 86:718-726.
30. Qu Y, Swerdlow NR, Weber M, Stouffer D, Parsons LH (2008). Quinelorane, a dopamine D3/D2 receptor agonist, reduces prepulse inhibition of startle and ventral pallidal GABA efflux: time course studies. Pharmacol Biochem Behav 90:686-690.
31. Ralph RJ, Caine SB (2005). Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129 x 1/SvJ, C57BL/6J, and DBA/2J mice. J Pharmacol Exp Ther 312:733-741.
32. Ralph RJ, Caine SB (2007). Effects of selective dopamine D1-like and D2-like agonists on prepulse inhibition of startle in inbred C3H/HeJ, SPRET/EiJ, and CAST/EiJ mice. Psychopharmacology (Berl) 191:731-739.
33. Ralph RJ, Varty GB, Kelly MA, Wang YM, Caron MG, Rubinstein M, et al. (1999). The dopamine D2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. J Neurosci 19:4627-4633.
34. Ralph-Williams RJ, Lehmann-Masten V, Otero-Corchon V, Low MJ, Geyer MA (2002). Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice. J Neurosci 22:9604-9611.
35. Ralph-Williams RJ, Lehmann-Masten V, Geyer MA (2003). Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice. Neuropsychopharmacology 28:108-118.
36. Risbrough VB, Masten VL, Caldwell S, Paulus MP, Low MJ, Geyer MA (2006). Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice. Neuropsychopharmacology 31:2349-2358.
37. Roussos P, Giakoumaki SG, Bitsios P (2008). The dopamine D(3) receptor Ser9Gly polymorphism modulates prepulse inhibition of the acoustic startle reflex. Biol Psychiatry 64:235-240.
38. Russig H, Spooren W, Durkin S, Feldon J, Yee BK (2004). Apomorphine-induced disruption of prepulse inhibition that can be normalised by systemic haloperidol is insensitive to clozapine pretreatment. Psychopharmacology (Berl) 175:143-147.
39. Schmauss C (2000). A single dose of methamphetamine leads to a long term reversal of the blunted dopamine D1 receptor-mediated neocortical c-fos responses in mice deficient for D2 and D3 receptors. J Biol Chem 275:38944-38948.
40. Semenova S, Geyer MA, Sutcliffe JG, Markou A, Hedlund PB (2008). Inactivation of the 5-HT(7) receptor partially blocks phencyclidine-induced disruption of prepulse inhibition. Biol Psychiatry 63:98-105.
41. Siuciak JA, Fujiwara RA (2004). The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors. Psychopharmacology (Berl) 175:163-169.
42. Svensson K, Carlsson A, Huff RM, Kling-Petersen T, Waters N (1994). Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors. Eur J Pharmaco 263:235-243.
43. Swerdlow NR, Lelham SA, Sutherland OAN, Chang WL, Sassen SD, Talledo JA (2009). Pramipexole effects on startle gating in rats and normal men. Psychopharmacology (Berl) 205:689-698.
44. Talledo JA, Owens ANS, Schortinghuis T, Swerdlow NR (2009). Amphetamine effects on startle gating in normal women and female rats. Psychopharma-cology 204:165-175.
45. Ukai M, Okuda A (2003). Endomorphin-1, an endogenous mu-opioid receptor agonist, improves apomorphine-induced impairment of prepulse inhibition in mice. Peptides 24:741-744.
46. Van den Buuse M, Martin S, Brosda J, Leck KJ, Matthaei KI, Hendry I (2005). Enhanced effect of dopaminergic stimulation on prepulse inhibition in mice deficient in the alpha subunit of G(z). Psychopharmacology (Berl) 183:358-367.
47. Weber M, Chang WL, Breier M, Ko D, Swerdlow NR (2008). Heritable strain differences in sensitivity to the startle gating-disruptive effects of D2 but not D3 receptor stimulation. Behav Pharmacol 19:786-795.
48. Weber M, Chang WL, Durbin JP, Park PE, Luedtke RR, Mach RH, Swerdlow NR (2009). Using prepulse inhibition to detect functional D3 receptor antagonism: effects of WC10 and WC44. Pharmacol Biochem Behav 93:141-147.
49. Xi ZX, Gilbert JG, Pak AC, Ashby CR Jr, Heidbreder CA, Gardner EL (2005). Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost-variable-payoff fixed-ratio cocaine self-administration in rats. Eur J Neurosci 21:3427-3438.
50. Yano K, Koda K, Ago Y, Kobayashi H, Kawasaki T, Takuma K, Matsuda T (2009). Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in mice. Br J Pharmacol 156:173-180.
51. Yee BK, Russig H, Feldon J (2004). Apomorphine-induced prepulse inhibition disruption is associated with a paradoxical enhancement of prepulse stimulus reactivity. Neuropsychopharmacology 29:240-248.
52. Zhou Y, Adomako-Mensah J, Yuferov V, Ho A, Zhang J, Xu M, Kreek M (2007). Effects of acute 'binge' cocaine on mRNA levels of mu opioid receptor and neuro-peptides in dopamine D1 or D3 receptor knockout mice. Synapse 61:50-59.